When Is a Test “Genetic?” The Case of Multi-Cancer Early Detection Tests
Multi-cancer early detection (MCED) tests are increasingly popular. Are these tests "genetic," and if so, can insurers use them in the risk assessment process? This article reviews definitions of genetic tests. It then reviews the motivation for limiting insurers' access to genetic tests and examines the wording in the legislation in 3 English speaking jurisdictions. It then attempts to establish whether MECD results are included in the legislation.
Authors
- Timothy Meagher
Publication Details
- Journal
- Journal of Insurance Medicine
- Published
- 2026-06-16
- DOI
- https://doi.org/10.17849/insm-53-2-1-4.1b
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00